Tenpoint Therapeutics appoints Stephen S. Lane, MD, as Chief Medical Officer. Ophthalmology luminary and former Alcon CMO joins Tenpoint Therapeutics April 7, 2026 Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the executive team and oversee the company's clinical development strategy, medical affairs and pharmacovigilance. Dr. Lane brings significant ophthalmology leadership experience in clinical practice and the pharmaceutical industry, most recently serving as CMO and Head of Medical Safety at Alcon, Inc. He is recognized as a world-renowned ophthalmologist with more than 40 years of experience. Dr. Lane is the past President of the American Society of Cataract and Refractive Surgery (ASCRS), a former member of the Committee of Secretaries at the American Academy of Ophthalmology (AAO), a former Board Member and Officer of the International Society of Refractive Surgery (ISRS) and a Board Member of the Minnesota Academy of Ophthalmology. He has been honored with numerous awards, including the AAO Honor Award, Senior Achievement Award and Secretariat Award. "Dr. Lane is a highly respected ophthalmology leader whose experience spans clinical practice, product development and medical leadership at the highest levels of the industry," said Henric Bjarke, chief executive officer of Tenpoint Therapeutics. "He is exceptionally well suited to help drive Tenpoint Therapeutics as we advance innovative therapies for the aging eye and enter this next stage of commercial growth." Career highlights. Throughout his career, Dr. Lane has contributed extensively to clinical research and education, participating in more than 50 clinical trials, delivering over 400 lectures globally, presenting six domestic and international medical lectures and authoring numerous academic articles and book chapters. He also holds several biomedical patents. He currently serves as chief executive officer of the Holland Foundation for Sight Restoration, a nonprofit organization focused on establishing centers of excellence for ocular stem cell transplantation and advancing the education of corneal surgeons, and as a clinical professor of ophthalmology at the University of Minnesota. "I am excited to join Tenpoint Therapeutics at a time of significant opportunity for the Company and the field of ophthalmology," said Dr. Lane. "Tenpoint Therapeutics' dedication to advancing innovative treatments for the aging eye aligns closely with my passion for improving patient outcomes. I look forward to working with the team to further develop and deliver solutions that address the unmet needs of both patients and the eye care professionals who care for them." Dr. Lane earned his medical degree from the University of Minnesota, completed his ophthalmology residency at Pennsylvania State University and is fellowship-trained in cornea/external disease, anterior segment surgery and refractive surgery.

Tenpoint Therapeutics has appointed Stephen S. Lane, MD, as chief medical officer. Dr Lane will oversee the company's clinical development strategy, medical affairs and pharmacovigilance. Dr Lane brings over 40 years of ophthalmology experience, most recently serving as chief medical officer and head of medical safety at Alcon. He is past president of the American Society of Cataract and Refractive Surgery and has participated in more than 50 clinical trials whilst delivering over 400 lectures globally. Tenpoint Therapeutics is a global ophthalmic pharmaceutical company focused on commercialising YUVEZZI, the first dual-agent eye drop for treating presbyopia, which affects approximately 2 billion people worldwide. Dr Lane earned his medical degree from the University of Minnesota.

Tenpoint Therapeutics and PHIL Inc. have launched a direct-to-patient cash programme for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia treatment. The programme aims to improve access to the therapy through affordable pricing, home delivery and dedicated support. Presbyopia affects nearly 128 million Americans and approximately 2 billion people globally, with many patients going untreated due to high out-of-pocket costs and limited access. The partnership seeks to reduce these barriers and support long-term treatment adherence. YUVEZZI contains carbachol and brimonidine tartrate ophthalmic solution at 2.75%/0.1% concentration. PHIL operates a healthcare technology platform that connects pharmaceutical manufacturers with patients to provide more convenient and affordable medication access.